Literature DB >> 24925522

Biological variability in serum anti-Müllerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women.

K A Kissell1, M R Danaher2, E F Schisterman3, J Wactawski-Wende4, K A Ahrens3, K Schliep3, N J Perkins3, L Sjaarda3, J Weck3, S L Mumford5.   

Abstract

STUDY QUESTION: Does serum anti-Müllerian hormone (AMH) vary significantly throughout both ovulatory and sporadic anovulatory menstrual cycles in healthy premenopausal women? SUMMARY ANSWER: Serum AMH levels vary statistically significantly across the menstrual cycle in both ovulatory and sporadic anovulatory cycles of healthy eumenorrheic women. WHAT IS KNOWN ALREADY: Studies to date evaluating serum AMH levels throughout the menstrual cycle have conflicting results regarding intra-woman cyclicity. No previous studies have evaluated an association between AMH and sporadic anovulation. STUDY DESIGN, SIZE, DURATION: We conducted a prospective cohort study of 259 regularly menstruating women recruited between 2005 and 2007. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Women aged 18-44 years were followed for one (n = 9) or two (n = 250) menstrual cycles. Anovulatory cycles were defined as any cycle with peak progesterone concentration ≤5 ng/ml and no serum LH peak on the mid or late luteal visits. Serum AMH was measured at up to eight-time points throughout each cycle. MAIN RESULTS AND THE ROLE OF CHANCE: Geometric mean AMH levels were observed to vary across the menstrual cycle (P < 0.01) with the highest levels observed during the mid-follicular phase at 2.06 ng/ml, decreasing around the time of ovulation to 1.79 ng/ml and increasing thereafter to 1.93 (mid-follicular versus ovulation, P < 0.01; ovulation versus late luteal, P = 0.01; mid-follicular versus late luteal, P = 0.05). Patterns were similar across all age groups and during ovulatory and anovulatory cycles, with higher levels of AMH observed among women with one or more anovulatory cycles (P = 0.03). LIMITATIONS, REASONS FOR CAUTION: Ovulatory status was not verified by direct visualization. AMH was analyzed using the original Generation II enzymatically amplified two-site immunoassay, which has been shown to be susceptible to assay interference. Thus, absolute levels should be interpreted with caution, however, patterns and associations remain consistent and any potential bias would be non-differential. WIDER IMPLICATIONS OF THE
FINDINGS: This study demonstrates a significant variation in serum AMH levels across the menstrual cycle regardless of ovulatory status. This variability, although statistically significant, is not large enough to warrant a change in current clinical practice to time AMH measurements to cycle day/phase. STUDY FUNDING/COMPETING INTERESTS: This research was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD (Contracts # HHSN275200403394C, HHSN275201100002I Task 1 HHSN27500001). The authors have no conflicts of interest to declare. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  anovulation; anti-Müllerian hormone; menstrual cycle

Mesh:

Substances:

Year:  2014        PMID: 24925522      PMCID: PMC4093994          DOI: 10.1093/humrep/deu142

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  46 in total

1.  Prediction of ovulation by urinary hormone measurements with the home use ClearPlan Fertility Monitor: comparison with transvaginal ultrasound scans and serum hormone measurements.

Authors:  H M Behre; J Kuhlage; C Gassner; B Sonntag; C Schem; H P Schneider; E Nieschlag
Journal:  Hum Reprod       Date:  2000-12       Impact factor: 6.918

2.  Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation.

Authors:  Antonio La Marca; Stefania Malmusi; Simone Giulini; Leo Fischer Tamaro; Raoul Orvieto; Paola Levratti; Annibale Volpe
Journal:  Hum Reprod       Date:  2004-09-30       Impact factor: 6.918

3.  Effect of daily fiber intake on reproductive function: the BioCycle Study.

Authors:  Audrey J Gaskins; Sunni L Mumford; Cuilin Zhang; Jean Wactawski-Wende; Kathleen M Hovey; Brian W Whitcomb; Penelope P Howards; Neil J Perkins; Edwina Yeung; Enrique F Schisterman
Journal:  Am J Clin Nutr       Date:  2009-08-19       Impact factor: 7.045

4.  Serum müllerian-inhibiting substance levels during normal menstrual cycles.

Authors:  C L Cook; Y Siow; S Taylor; M E Fallat
Journal:  Fertil Steril       Date:  2000-04       Impact factor: 7.329

5.  Urinary follicle-stimulating hormone peak as a biomarker for estimating the day of ovulation.

Authors:  Hongxia Li; Jiangang Chen; James W Overstreet; Steven T Nakajima; Bill L Lasley
Journal:  Fertil Steril       Date:  2002-05       Impact factor: 7.329

6.  Anti-mullerian hormone as a marker of ovarian reserve.

Authors:  Kelton P Tremellen; Michele Kolo; Alan Gilmore; Dharmawijaya N Lekamge
Journal:  Aust N Z J Obstet Gynaecol       Date:  2005-02       Impact factor: 2.100

Review 7.  The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest.

Authors:  Sophie Jonard; Didier Dewailly
Journal:  Hum Reprod Update       Date:  2004 Mar-Apr       Impact factor: 15.610

8.  Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.

Authors:  Pascal Pigny; Emilie Merlen; Yann Robert; Christine Cortet-Rudelli; Christine Decanter; Sophie Jonard; Didier Dewailly
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

9.  Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception.

Authors:  Scott M Nelson; Robin W Yates; Helen Lyall; Maybeth Jamieson; Isabel Traynor; Marco Gaudoin; Paul Mitchell; Pat Ambrose; Richard Fleming
Journal:  Hum Reprod       Date:  2009-01-10       Impact factor: 6.918

10.  Reliability and validity of Canada's Physical Activity Monitor for assessing trends.

Authors:  Cora Lynn Craig; Storm J Russell; Christine Cameron
Journal:  Med Sci Sports Exerc       Date:  2002-09       Impact factor: 5.411

View more
  24 in total

1.  Anti-Müllerian hormone levels in nurses working night shifts.

Authors:  Candice Y Johnson; Lauren J Tanz; Christina C Lawson; Penelope P Howards; Elizabeth R Bertone-Johnson; A Heather Eliassen; Eva S Schernhammer; Janet W Rich-Edwards
Journal:  Arch Environ Occup Health       Date:  2019-04-04       Impact factor: 1.663

2.  c-JUN Dimerization Protein 2 (JDP2) Is a Transcriptional Repressor of Follicle-stimulating Hormone β (FSHβ) and Is Required for Preventing Premature Reproductive Senescence in Female Mice.

Authors:  Carrie R Jonak; Nancy M Lainez; Lacey L Roybal; Alexa D Williamson; Djurdjica Coss
Journal:  J Biol Chem       Date:  2016-12-22       Impact factor: 5.157

3.  Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Louise A Brinton; Brian L Egleston; Roni Falk; Renée T Fortner; Kathy J Helzlsouer; Annika Idahl; Rudolph Kaaks; Eva Lundin; Melissa Merritt; Charlotte Onland-Moret; Sabina Rinaldi; María-José Sánchez; Sabina Sieri; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley Tworoger; Kala Visvanathan; Vittorio Krogh; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Wei Zheng; Joanne F Dorgan
Journal:  Fertil Steril       Date:  2017-04       Impact factor: 7.329

4.  Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys.

Authors:  D H Abbott; B H Rayome; D A Dumesic; K C Lewis; A K Edwards; K Wallen; M E Wilson; S E Appt; J E Levine
Journal:  Hum Reprod       Date:  2017-04-01       Impact factor: 6.918

5.  Multi-center clinical evaluation of the Access AMH assay to determine AMH levels in reproductive age women during normal menstrual cycles.

Authors:  Clarisa R Gracia; Sanghyuk S Shin; Maureen Prewitt; Janna S Chamberlin; Lori R Lofaro; Kristin L Jones; Marta Clendenin; Katherine E Manzanera; Dennis L Broyles
Journal:  J Assist Reprod Genet       Date:  2018-03-14       Impact factor: 3.412

6.  Intrauterine, Infant, and Childhood Factors and Ovarian Reserve in Young African American Women.

Authors:  Kristen Upson; Helen B Chin; Erica E Marsh; Donna D Baird
Journal:  J Womens Health (Larchmt)       Date:  2019-01-14       Impact factor: 2.681

7.  One-year impact of bariatric surgery on serum anti-Mullerian-hormone levels in severely obese women.

Authors:  Clara Vincentelli; Marie Maraninchi; René Valéro; Sophie Béliard; Flavia Maurice; Olivier Emungania; Bruno Berthet; Elise Lombard; Anne Dutour; Bénédicte Gaborit; Blandine Courbiere
Journal:  J Assist Reprod Genet       Date:  2018-05-12       Impact factor: 3.412

8.  Cadmium Exposure and Ovarian Reserve in Women Aged 35-49 Years: The Impact on Results From the Creatinine Adjustment Approach Used to Correct for Urinary Dilution.

Authors:  Kristen Upson; Katie M O'Brien; Janet E Hall; Erik J Tokar; Donna D Baird
Journal:  Am J Epidemiol       Date:  2021-01-04       Impact factor: 4.897

9.  Serum anti-Müllerian hormone levels in women are unstable in the postpartum period but return to normal within 5 months: a longitudinal study.

Authors:  Michael W Pankhurst; Annelien C de Kat; Shirley Jones; Frank J M Broekmans; Benjamin J Wheeler
Journal:  Endocrine       Date:  2020-09-11       Impact factor: 3.633

10.  Is Anti-Müllerian Hormone Associated With Fecundability? Findings From the EAGeR Trial.

Authors:  Shvetha M Zarek; Emily M Mitchell; Lindsey A Sjaarda; Sunni L Mumford; Robert M Silver; Joseph B Stanford; Noya Galai; Mark V White; Karen C Schliep; Alan H DeCherney; Enrique F Schisterman
Journal:  J Clin Endocrinol Metab       Date:  2015-09-25       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.